ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice
Joint Authors
Schlaich, Markus P.
Goring, Harald
Curran, Joanne E.
Blangero, John
Matthews, V. B.
Herat, Lakshini Y.
Johnson, Matthew P.
Rudnicka, Caroline
Moses, Eric K.
Hricova, Jana
Sang, Qing-Xiang Amy
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-02-07
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Obesity is one of the most prevalent metabolic diseases in the Western world and correlates directly with insulin resistance, which may ultimately culminate in type 2 diabetes (T2D).
We sought to ascertain whether the human metalloproteinase A Disintegrin and Metalloproteinase 19 (ADAM19) correlates with parameters of the metabolic syndrome in humans and mice.
To determine the potential novel role of ADAM19 in the metabolic syndrome, we first conducted microarray studies on peripheral blood mononuclear cells from a well-characterised human cohort.
Secondly, we examined the expression of ADAM19 in liver and gonadal white adipose tissue using an in vivo diet induced obesity mouse model.
Finally, we investigated the effect of neutralising ADAM19 on diet induced weight gain, insulin resistance in vivo, and liver TNF-α levels.
Significantly, we show that, in humans, ADAM19 strongly correlates with parameters of the metabolic syndrome, particularly BMI, relative fat, HOMA-IR, and triglycerides.
Furthermore, we identified that ADAM19 expression was markedly increased in the liver and gonadal white adipose tissue of obese and T2D mice.
Excitingly, we demonstrate in our diet induced obesity mouse model that neutralising ADAM19 therapy results in weight loss, improves insulin sensitivity, and reduces liver TNF-α levels.
Our novel data suggest that ADAM19 is pro-obesogenic and enhances insulin resistance.
Therefore, neutralisation of ADAM19 may be a potential therapeutic approach to treat obesity and T2D.
American Psychological Association (APA)
Herat, Lakshini Y.& Rudnicka, Caroline& Sang, Qing-Xiang Amy& Curran, Joanne E.& Johnson, Matthew P.& Moses, Eric K.…[et al.]. 2017. ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice. Mediators of Inflammation،Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1188645
Modern Language Association (MLA)
Herat, Lakshini Y.…[et al.]. ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice. Mediators of Inflammation No. 2017 (2017), pp.1-9.
https://search.emarefa.net/detail/BIM-1188645
American Medical Association (AMA)
Herat, Lakshini Y.& Rudnicka, Caroline& Sang, Qing-Xiang Amy& Curran, Joanne E.& Johnson, Matthew P.& Moses, Eric K.…[et al.]. ADAM19: A Novel Target for Metabolic Syndrome in Humans and Mice. Mediators of Inflammation. 2017. Vol. 2017, no. 2017, pp.1-9.
https://search.emarefa.net/detail/BIM-1188645
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1188645